ArticleAnnals of hematology2024

Safety of Rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin's lymphoma: a retrospective study.

Nina K Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.